

PARTICULARS TO APPEAR ON THE OUTER PACKAGE Plastic box

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Purevax FeLV suspension for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Per dose of 0.5 ml or 1 ml:

FeLV recombinant Canarypox virus (vCP97) $\geq 10^{7.2}$ CCID₅₀¹

3. PACKAGE SIZE

10 x 1 ml (10 x 1 dose)

20 x 1 ml (20 x 1 dose)

50 x 1 ml (50 x 1 dose)

10 x 0.5 ml (10 x 1 dose)

20 x 0.5 ml (20 x 1 dose)

50 x 0.5 ml (50 x 1 dose)

4. TARGET SPECIES

Cats.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Subcutaneous use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {dd/mm/yyyy}

Once broached use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Store and transport refrigerated.

Protect from light.

Do not freeze.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica GmbH

14. MARKETING AUTHORISATION NUMBERS

Vm 61700/5066

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Suspension bottle

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Purevax FeLV



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

0.5 ml or 1 ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {dd/mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Purevax FeLV suspension for injection

2. Composition

Per dose of 1 ml or 0.5 ml :

Active substances:

FeLV recombinant Canarypox virus (vCP97) $\geq 10^{7.2}$ CCID₅₀¹

¹cell culture infective dose 50%

Clear colourless liquid with presence of cell debris in suspension.

3. Target species

Cats

4. Indications for use

Active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.

Onset of immunity: 2 weeks after primary vaccination course.

Duration of immunity: 1 year after the last vaccination.

5. Contraindications

None.

6. Special warnings

Special warnings:

Vaccine healthy animals only.

Special precautions for safe use in the target species:

It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination. Vaccination of FeLV positive cats is of no benefit.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

Do not use during the whole pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Boehringer Ingelheim non-adjuvanted vaccine range (various combinations of feline viral rhinotracheitis, calicivirosis, panleukopenia and chlamydiosis components) and/or administered the same day but not mixed with Boehringer Ingelheim adjuvanted vaccine against rabies.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

Overdose:

No adverse events other than those already mentioned in section "Adverse events" have been observed.

Major incompatibilities:

Do not mix with any other veterinary medical product, except those mentioned above.

7. Adverse events

Cats:

Very common (>1 animal / 10 animals treated):

Injection site nodule.¹

Lethargy, hyperthermia.²

Very rare (<1 animal / 10 000 animals treated, including isolated reports):

Anorexia, emesis.

Hypersensitivity reaction, anaphylaxis.³

1 Small (< 2 cm) , regresses within 1 to 4 weeks.

2 Lasting usually for 1 day, exceptionally for 2 days.

3 If such reactions occur, appropriate treatment is recommended.

May evolve to a more severe condition (anaphylaxis). If such reactions occur, appropriate treatment is recommended.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Subcutaneous use.

Administer one dose of 1 ml or 0.5 ml of vaccine (depending on the presentation chosen) according to the following schedule:

Basic vaccination: first injection: from 8 weeks of age,
second injection: 3 to 5 weeks later.
Revaccination: annual

9. Advice on correct administration

Shake well before use.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.
Store and transport refrigerated (2 °C – 8 °C).
Protect from light.
Do not freeze.

Do not use this veterinary medical product after the expiry date, which is stated on the label after Exp.

Shelf life after first opening the immediate packaging: use immediately.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

13. Classification of veterinary medicinal products

Veterinary medical product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 61700/5066

Plastic box containing:
10, 20 or 50 x 1 ml of vaccine or
10, 20 or 50 x 0.5 ml of vaccine.

Not all pack sizes may be marketed.

15. PID link (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:

Boehringer Ingelheim Vetmedica GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

Manufacturer responsible for batch release:

Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation
69800 Saint-Priest
France

Local representatives and contact details to report suspected adverse reactions:

Boehringer Ingelheim Animal Health UK Ltd., United Kingdom
Tel: + 44 1344 746957

17. Other information

Vaccine against feline leukaemia.

The vaccine strain is a recombinant canarypox virus expressing the *env* and *gag* genes of FeLV-A. Under field conditions, only sub-group A is infective and immunisation against sub-group A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat. As a consequence, the vaccine induces an immune status against feline leukaemia virus.

POM-V

Approved 03 June 2025
Gavin Hall